Good Therapeutics is an early-stage biotechnology company based in Seattle, Washington. They are developing "context-dependent" protein drugs that sense biomarkers and respond with a therapeutic activity. Their goal is to make safer, more effective drugs that act only when and where they are needed, limiting systemic toxicity without reducing therapeutic efficacy.
The core technology is an algorithm for designing allosterically-regulated proteins. These proteins change their conformation (shape) when they bind a biomarker or metabolite, and in doing so activate a therapeutic domain. The company is currently focused on immuno-oncology applications of the technology.